تحولات نموذج البحث و التطوير الصيدلاني

Abstract EN

The global pharmaceutical environment transformations lead to modifying the industry business model from pharma 1.

0 to pharma 4.

0.

One of the greatest changes is the R&D productivity crisis, which is figured by the rise of R&D costs and budgets and the decline of the new molecular entities numbers.

This fact imposes the necessity of amending the big pharma behaviours about how to follow their innovations: the gradual transition from the blockbuster closed innovation model to the open innovation model is settled The pharmaceutical open innovation has multi strategies, it is also based on biotechnology and personalized medicine and tends further to digitalization.